Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
PR Newswire
BOSTON, July 8, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.
The call can be accessed via teleconference at: Q1 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/r8e9tnfy
A replay of the conference call and webcast will be available for one year beginning on August 6, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts | |
Olga Guyette, VP - Investor Relations & Treasury | David Trenk, Senior Manager - Investor Relations |
(781) 356-9763 | (203) 733-4987 |
|
|
Media Contact | |
Josh Gitelson, Senior Director - Global Communications | |
(781) 356-9776 | |
SOURCE Haemonetics Corporation
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States